Urgent.News

What's breaking now, across thousands of outlets.

Editions

Health & Medicine

Want to join a clinical trial? Distance, insurance and hidden costs can stand in the way

Connecting people with clinical trials is complicated—even if people identify a promising match, there's a slew of potentially thorny factors, including geographic incompatibility and financial and time considerations.

Want to join a clinical trial? Distance, insurance and hidden costs can stand in the way

Joining a clinical trial may seem like an appealing prospect, yet various obstacles can prevent individuals from participating. Even if someone identifies a suitable trial, factors such as location, financial burden, and time constraints can deter them. A recent survey of over 2,000 adults revealed that while 71% would consider joining a clinical trial, two-thirds reported never receiving any discussion from their healthcare provider about the option.

Clinical trials play a crucial role in advancing medical treatments, yet obtaining the necessary real-world data for FDA approval proves to be a challenging endeavor. Approximately 86% of clinical trials fail to meet their recruitment targets within the designated timeframe. Beyond the initial hurdle of recruitment, retaining participants throughout the trial presents its own set of challenges, as noted by Alan Balch, executive board chair at the Patient Advocate Foundation.

The American Cancer Society highlights that clinical trials provide an opportunity for patients with serious illnesses to potentially extend their life or improve their quality of life. Even if the therapy being tested is not the best standard of care, patients receive close monitoring and the highest level of treatment. Some patients participate to contribute to scientific advancements, while others hope to access cutting-edge therapies not yet available to the general public.

Despite the interest in clinical trial participation, most patients remain unaware of how to find a trial. Primary care physicians, while willing to refer patients to trials, often struggle to identify eligible trials due to time constraints. Patients themselves may face difficulties in locating trials, although some patient advocacy groups offer navigation services and disease-specific trial information. When enrolled, participants must weigh the potential benefits against any associated medical or non-medical expenses.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Health & Medicine

Chong Kun Dang Signs KIO-301 Deal

Chong Kun Dang has joined hands with a US pharmaceutical company to treat a rare inherited retinal disease estimated to affect more than 10,000 patients in South Korea.Chong Kun Dang signed a…

  • Chong Kun Dang partners with Kiora Pharmaceuticals for KIO-301 development.
  • KIO-301 targets retinitis pigmentosa, affecting over 10,000 South Koreans.
  • Collaboration aims to expedite domestic clinical and approval processes.

More from Friday 21 August →